The distribution of common adverse drug events reported for all other COVID-19 EUA products for comparison to Nirmatrelvir/Ritonavir.
figure
posted on 2024-12-31, 18:47 authored by Ji Sun, Xuanyu Deng, Juanjuan Huang, Gefei He, Shiqiong HuangPT, preferred term. N, number of preferred terms.
(TIF)
History
Usage metrics
Categories
Keywords
reporting odds rationew adverse reactionshigh signal intensityadverse reactions recordedadverse reaction signalsachieved considerable results98 ), diarrhea53 ), chromaturiaprompting clinical attentionrational drug useprimary suspected drugxlink "> nirmatrelvirfaers 25 ),clinical studiesdrug efficacythird quarterstudy aimsreal worldmultiple systemmedication safetylittle researchhighly relevanteffective applicationeffective agentdata miningcolored stoolsantiviral treatment
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC